Maravai LifeSciences Holdings, Inc. · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$3.56
−$0.00 (−0.14%) 4:00 PM ET
Pre-market$3.55
−$0.01 (−0.14%) 11:25 PM ET
Prev closePrevC$3.56
OpenOpen$3.54
Day highHigh$3.60
Day lowLow$3.50
VolumeVol1,344,645
Avg volAvgVol1,131,553
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$516.28M
P/E ratio
-3.95
FY Revenue
$185.74M
EPS
-0.90
Gross Margin
18.30%
Sector
Healthcare
AI report sections
BULLISH
MRVI
Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences shows improving short- and medium-term price performance with the stock trading in the upper half of its 52-week range and above key moving averages, supported by bullish momentum indicators. At the same time, fundamentals are under pressure with negative earnings, deeply negative margins, and negative free cash flow, while valuation multiples remain moderate rather than distressed. Elevated short interest, negative news flow related to investigations, and high leverage relative to equity add to the overall risk backdrop.
MARAVAI INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Maravai LifeSciences is under investigation for potential financial reporting irregularities, including revenue recognition errors and potential goodwill impairment, which led to a significant stock price drop.
Company identified revenue recognition errors, material weakness in internal controls, potential goodwill impairment, and experienced a 21.70% stock price decline following the announcement
MARAVAI ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Maravai LifeSciences is under investigation for potential financial reporting irregularities, including revenue recognition errors and potential goodwill impairment, which led to a significant stock price drop.
The company disclosed a $3.9 million revenue recognition error, identified material weakness in internal controls, required additional time to assess potential goodwill impairment, and experienced a 21.70% stock price decline following these revelations
MARAVAI ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Law firm investigating potential claims against Maravai LifeSciences for alleged financial reporting irregularities, including revenue recognition errors and potential goodwill impairment during fiscal 2024.
Company disclosed revenue recognition errors, material weakness in internal controls, potential goodwill impairment, and experienced a 21.70% stock price drop following the announcement
MRVI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
A class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. (MRVI) for alleged violations of federal securities laws, including inaccurate revenue recognition and overstated goodwill.
The article alleges that the company made materially false and/or misleading statements, failed to disclose material adverse facts about its business, operations, and prospects, including issues with revenue recognition and overstated goodwill.
NegativeBenzinga• Prnewswire
MRVI Investors Reminded of Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Investors who purchased Maravai LifeSciences Holdings, Inc. securities between August 7, 2024 and February 24, 2025 are encouraged to join a class action lawsuit against the company for alleged securities fraud violations.
The company is accused of making false and misleading statements, failing to maintain adequate internal controls, and improperly recognizing revenue, which led to investor losses.
NegativeGlobeNewswire Inc.• N/A
Levi & Korsinsky Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 – MRVI
Levi & Korsinsky, LLP notifies investors in Maravai LifeSciences Holdings, Inc. of a class action securities lawsuit related to alleged securities fraud between August 7, 2024 and February 24, 2025.
The article mentions a class action lawsuit against Maravai LifeSciences for alleged securities fraud, which suggests negative sentiment towards the company.
MRVI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Maravai LifeSciences Holdings, Inc. (MRVI) is facing a class action lawsuit alleging the company made materially false and/or misleading statements about its financial reporting, revenue recognition, and goodwill.
The article alleges that Maravai LifeSciences made materially false and/or misleading statements about its financial reporting, revenue recognition, and goodwill, which led to a class action lawsuit against the company.
NegativeGlobeNewswire Inc.• N/A
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AppLovin, Maravai, e.l.f. Beauty, and Skyworks Solutions and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has filed class action lawsuits against AppLovin, Maravai, e.l.f. Beauty, and Skyworks Solutions, alleging various financial irregularities and misleading statements by the companies.
The lawsuit alleges that Maravai lacked adequate internal controls over financial reporting, resulting in inaccurate revenue recognition and overstated goodwill.
Maravai LifeSciences Holdings, Inc. reported disappointing Q4 2024 earnings, leading to a significant downgrade by Stifel analysts and a securities class action lawsuit alleging improper accounting practices.
MRVIMaravai LifeSciences Holdingsearnings missanalyst downgradesecurities class action lawsuit
Sentiment note
The company reported weaker-than-expected Q4 2024 results, leading to a 50% reduction in Stifel's price target and a securities class action lawsuit alleging improper accounting practices.
NegativeGlobeNewswire Inc.• N/A
MRVI IMPORTANT DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Maravai Lifesciences Holdings, Inc. Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action – MRVI
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) securities between August 7, 2024 and February 24, 2025 of the important May 5, 2025 lead plaintiff deadline in a securities class action lawsuit.
MRVIMaravai Lifesciences Holdingssecurities class actiondeadline
Sentiment note
The article mentions that a securities class action lawsuit has been filed against Maravai Lifesciences Holdings, Inc. due to allegations of false and/or misleading statements and/or failure to disclose information related to revenue recognition, goodwill, and the company's business prospects.
NegativeGlobeNewswire Inc.• N/A
מועד אחרון חשוב לתביעה נגד MRVI: רוזן, יועץ למשקיעים מוכר, מעודד את משקיעי Maravai Lifesciences Holdings, Inc להבטיח ייעוץ לפני המועד האחרון החשוב של 5 במאי בתביעה ייצוגית בניירות ערך - MRVI
Rosen Law Firm reminds Maravai Lifesciences Holdings, Inc. (MRVI) investors of the important May 5 deadline to join a securities class action lawsuit. The lawsuit alleges that the company made false and misleading statements about its financial reporting, revenue recognition, and business prospects, causing investor losses.
MRVIMaravai Lifesciences Holdingssecurities class actioninvestor lawsuit
Sentiment note
The article discusses a securities class action lawsuit against Maravai Lifesciences Holdings, Inc., alleging the company made false and misleading statements that caused investor losses.
NegativeGlobeNewswire Inc.• Faruqi & Faruqi, Llp
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Maravai LifeSciences
Faruqi & Faruqi, LLP is investigating potential claims against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) for allegedly making false and/or misleading statements related to revenue recognition, goodwill, and internal controls.
The article alleges that Maravai LifeSciences made false and/or misleading statements related to revenue recognition, goodwill, and internal controls, which resulted in a significant drop in the company's share price.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
